A review analyzing what is COVID-19, its causes, pathogenesis, pathophysiology, and treatment

Authors

  • Mohamed Hoosen Suleman Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban 4013, South Africa

Keywords:

COVID-19, Pathogenesis, Pathophysiology, Treatment

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is believed to be the causative agent for the 2019 novel coronavirus (COVID-19). The COVID-19 disease which also started from bats had mutated and it is believed to have infected pangolins as its intermediate host. Mutations of the viral pathogen thereafter led to it infecting humans. COVID-19 is considered a zoonotic disease i.e. diseases that spread from animals to humans. Community transmission from human to human has largely contributed to increasing infection rates across the globe. When the novel coronavirus was first detected, it took just 69 days to infect 100000 patients, then increased to 200000 in 12 days, then 300000 in 4 days, and 400000 days in less than a day. As of 1 September 2021, there are well over two hundred and seventeen million cases worldwide. Of concern, at least four and a half million confirmed COVID-19 deaths have been recorded as of 1 September 2021. The World Health Organization (WHO) has advised that the COVID-19 pandemic is far from over.

Downloads

Download data is not yet available.

References

Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., ... & Zhou, Y. (2020). Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. International Journal of Infectious Diseases, 10, 10-16.

Shi, Z., & Hu, Z. (2008). A review of studies on animal reservoirs of the SARS coronavirus. Virus research, 133(1), 74-87.

Mohd, H. A., Al-Tawfiq, J. A., & Memish, Z. A. (2016). Middle east respiratory syndrome coronavirus (MERS-CoV) origin and animal reservoir. Virology journal, 13(1), 87.

White, P. J., & Enright, M. C. (2010). Mathematical models in infectious disease epidemiology. Infectious Diseases, 70.

Zheng, J. (2020). SARS-CoV-2: an emerging coronavirus that causes a global threat. International journal of biological sciences, 16(10), 1678.

Eisenberg, J. (2020). How scientists quantify the intensity of an outbreak like COVID-19. University of Michigan–Michigan Medicine Health Lab. Available online: https://labblog. uofmhealth. org/rounds/how-scientists-quantify-intensity-of-an-outbreak-likecovid-19.

Van Doremalen, N., Bushmaker, T., Morris, D. H., Holbrook, M. G., Gamble, A., Williamson, B. N., ... & Munster, V. J. (2020). Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. New England journal of medicine, 382(16), 1564-1567.

Fung, M., & Babik, J. M. (2021). COVID-19 in immunocompromised hosts: what we know so far. Clinical Infectious Diseases, 72(2), 340-350.

Kumpitsch, C., Koskinen, K., Schöpf, V., & Moissl-Eichinger, C. (2019). The microbiome of the upper respiratory tract in health and disease. BMC Biology, 17(1), 1-20.

Rajnik, M., Cascella, M., Cuomo, A., Dulebohn, S. C., & Di Napoli, R. (2021). Features, Evaluation, and Treatment of Coronavirus (COVID-19). Uniformed Services University Of The Health Sciences.

Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020). Nanotechnology for COVID-19: therapeutics and vaccine research. ACS nano, 14(7), 7760-7782.

Huang, Y., Yang, C., Xu, X. F., Xu, W., & Liu, S. W. (2020). Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica, 41(9), 1141-1149.

Tian, S., Xiong, Y., Liu, H., Niu, L., Guo, J., Liao, M., & Xiao, S. Y. (2020). Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Modern Pathology, 33(6), 1007-1014.

Koester, V. (2020). Coronavirus entering and replicating in a host cell. ChemViews, 5, e1000428.

Icho, T., & Wickner, R. B. (1989). The double-stranded RNA genome of yeast virus LA encodes its own putative RNA polymerase by fusing two open reading frames. Journal of Biological Chemistry, 264(12), 6716-6723.

Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., ... & Wu, J. (2020). Coronavirus infections and immune responses. Journal of medical virology, 92(4), 424-432.

Force, A. D. T., Ranieri, V. M., Rubenfeld, G. D., Thompson, B. T., Ferguson, N., Caldwell, E., ... & Slutsky, A. S. (2012). Acute respiratory distress syndrome. Jama, 307(23), 2526-2533.

Zhang, Y., Zhong, Y., Pan, L., & Dong, J. (2020). Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?. Drug discoveries & therapeutics, 14(2), 100-102.

Iturriaga, R., Del Rio, R., Idiaquez, J., & Somers, V. K. (2016). Carotid body chemoreceptors, sympathetic neural activation, and cardiometabolic disease. Biological research, 49(1), 1-9.

Arlati, S. (2019). Pathophysiology of acute illness and injury. In Operative Techniques and Recent Advances in Acute Care and Emergency Surgery, 11-42).

Mahase, E. (2020). Covid-19: what treatments are being investigated https://doi.org/10.1136/bmj.m1252.

Singh, R., & Vijayan, V. (2020). Chloroquine: a potential drug in the COVID-19 scenario. Transactions of the Indian National Academy of Engineering, 5, 399-410.

Zhao, H., Wald, J., Palmer, M., & Han, Y. (2018). Hydroxychloroquine-induced cardiomyopathy and heart failure in twins. Journal of thoracic disease, 10(1), E70.

Meini, S., Pagotto, A., Longo, B., Vendramin, I., Pecori, D., & Tascini, C. (2020). Role of Lopinavir/Ritonavir in the treatment of Covid-19: a review of current evidence, guideline recommendations, and perspectives. Journal of clinical medicine, 9(7), p.2050.

Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., ... & Pirmohamed, M. (2019). Drug repurposing: progress, challenges and recommendations. Nature reviews Drug discovery, 18(1), 41-58.

Harrison, C. (2020). Coronavirus puts drug repurposing on the fast track. Nature Biotechnology, 38(4), 379-381.

London, A. J., & Kimmelman, J. (2020). Against pandemic research exceptionalism. Science, 368(6490), 476-477.

Yousefifard, M., Zali, A., Ali, K. M., Neishaboori, A. M., Zarghi, A., Hosseini, M., & Safari, S. (2020). Antiviral therapy in management of COVID-19: a systematic review on current evidence. Archives of academic emergency medicine, 8(1).

Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., ... & Northwell COVID-19 Research Consortium. (2020). Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama, 323(20), 2052-2059.

Hernandez, A. V., Roman, Y. M., Pasupuleti, V., Barboza, J. J., & White, C. M. (2020). Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Annals of internal medicine, 173(4), 287-296.

Rossman, J. (2020, March). Can herd immunity really protect us from coronavirus. In World Economic Forum.

Trotter, C. L., & Maiden, M. C. (2009). Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert review of vaccines, 8(7), 851-861.

Cohen, J. (2020). With record-setting speed, vaccinemakers take their first shots at the new coronavirus. Science, 31.

Published

2021-09-07

How to Cite

Suleman, M. H. (2021). A review analyzing what is COVID-19, its causes, pathogenesis, pathophysiology, and treatment. International Research Journal of Advanced Science, 2(2), 33-38. Retrieved from https://irjas.com/index.php/sciencejournal/article/view/48

Issue

Section

Articles